Surface modified nevirapine nanosuspensions for viral reservoir targeting: In vitro and in vivo evaluation

International Journal of Pharmaceutics

Volumn 421, Issue 2, 2011, Pages 341-352

  Shegokar, Ranjita ^a,b   Singh, Kamalinder K ^a  

^a SNDT WOMEN S UNIVERSITY   (India)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

High pressure homogenization; HIV AIDS; Nanosuspensions; Nevirapine; Pharmacokinetics; Targeting

Indexed keywords

MACROGOL; NEVIRAPINE; POLYSACCHARIDE; SERUM ALBUMIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG COATING; DRUG SOLUTION; DRUG TARGETING; IN VITRO STUDY; IN VIVO STUDY; MALE; NANOANALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SURFACE PROPERTY; TISSUE DISTRIBUTION;

ANIMALS; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; DEXTRANS; DRUG COMPOUNDING; MACROPHAGES; MALE; MICE; NANOPARTICLES; NEVIRAPINE; POLYETHYLENE GLYCOLS; PRESSURE; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE INHIBITORS; SERUM ALBUMIN, BOVINE; SUSPENSIONS; TISSUE DISTRIBUTION;

EID: 81755174204     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.09.041     Document Type: Article

References (43)

1. M.M. Amiji, T.K. Vyas, and L.K. Shah Role of nanotechnology in HIV/AIDS treatment: potential to overcome the viral reservoir challenge Discov. Med. 6 2006 157 162
2. K.E. Anderson, B.R. Stevenson, and J.A. Rogers Folic acid-PEO-labeled liposomes to improve gastrointestinal absorption of encapsulated agents J. Control. Rel. 60 1999 189 198
3. N. Arulsudar, N. Subramanian, P. Mishra, R.K. Sharma, and R.S. Murthy Preparation, characterisation and biodistribution of 99mTc-labeled liposome encapsulated cyclosporine J. Drug Target. 11 2003 187 196
4. L. Baert, G. van't Klooster, W. Dries, M. Francois, A. Wouters, E. Basstanie, K. Iterbeke, F. Stappers, P. Stevens, L. Schueller, P. Van Remoortere, G. Kraus, P. Wigerinck, and J. Rosier Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment Eur. J. Pharm. Biopharm. 72 2009 502 508
5. G.M. Barratt Therapeutic applications of colloidal drug carriers Pharm. Sci. Technol. Today 3 2000 163 171
6. Blunk, T., 1994. Plasma protein adsorption onto colloidal drug carriers. Ph.D. Thesis. Department of Pharmacy, Freie Universität Berlin.
7. T. Blunk, D.F. Hochstrasser, J.C. Sanchez, B.W. Müller, and R.H. Müller Colloidal carriers for intravenous drug targeting: plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis Electrophoresis 14 1993 1382 1387
8. T. Blunk, M. Lück, A. Calvör, D.F. Hochstrasser, J.C. Sanchez, B.W. Müller, and R.H. Müller Kinetics of plasma protein adsorption on model particles for controlled drug delivery and drug targeting Eur. J. Pharm. Biopharm. 42 1996 262 268
9. G. Buckton Interfacial Phenomena in Drug Delivery and Targeting 1995 Harwood Academic Publishers GmbH Switzerland pp. 154-155
10. T.W. Chun, and A.S. Fauci Latent reservoirs of HIV: obstacles to the eradication of virus Proc. Natl. Acad. Sci. U.S.A. 96 1999 10958 10961
11. A.A. Date, M.D. Joshi, and V.B. Patravale Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles Adv. Drug Deliv. Rev. 59 2007 505 521
12. S.S. Davis, S. Douglas, L. Illum, P.D.E. Jones, E. Mak, and R.H. Müller Targeting of colloidal carriers and the role of surface proteins G. Gregoriadis, J. Senior, G. Poste, Targeting of Drugs with Synthetic Systems 1986 Plenum 123
13. R. Deng, and J.P. Balthasar Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia Blood 109 2007 2470 2476
14. A. Desormeaux, and M.G. Bergeron Lymphoid tissue targeting of anti-HIV drugs using liposomes Methods Enzymol. 391 2005 330 351
15. J. Embretson, M. Zupancic, J.L. Ribas, A. Burke, P. Racz, K. Tenner-Tacz, and A.T. Haase Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS Nature 362 1993 359 362
16. ExPASy, Proteomics Server. www.expasy.org.
17. C. Ferri, M. Colaci, L. Battolla, D. Giuggioli, and M. Sebastiani Thymus alterations and systemic sclerosis Rheumatology (Oxford) 45 2006 72 75
18. F. Gimenez, C. Fernandez, and A. Mabondzo Transport of HIV protease inhibitors through the blood-brain: brain as a sanctuary site for HIV during HIV-1 encephalitis J. Acquir. Immune Defic. Syndr. 35 2004 102 105
19. T. Govender, E. Ojewole, P. Naidoo, and I. Mackraj Polymeric nanoparticles for enhancing antiretroviral drug therapy Drug Deliv. 15 2008 493 501
20. A.S. Ham, M.R. Cost, A.B. Sassi, C.S. Dezzutti, and L.C. Rohan Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles Pharm. Res. 26 2009 502 511
21. R. Ho Tsong Fang, A.D. Colantonio, and C.H. Uittenbogaart The role of the thymus in HIV infection: a 10 year perspective AIDS 22 2008 171 184
22. M.L. Immordino, F. Dosio, and L. Cattel Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential Int. J. Nanomed. 1 2006 297 315
23. E.C. Kang, K. Akiyoshi, and J. Sunamoto Partition of polysaccharide- coated liposomes in aqueous two-phase systems Int. J. Biol. Macromol. 16 1994 348 353
24. O. Kayser, and A.F. Kiderlen Delivery strategies for antiparasitics Expert. Opin. Investig. Drugs 12 2003 197 207
25. A.L. Klibanov, B.A. Khaw, N. Nossiff, S.M. O'Donnell, L. Huang, M.A. Slinkin, and V.P. Torchilin Targeting of macromolecular carriers and liposomes by antibodies to myosin heavy chain Am. J. Physiol. 261 1991 60 65
26. X. Li, and W.K. Chan Transport, metabolism and elimination mechanisms of anti-HIV agents Adv. Drug Deliv. Rev. 39 1999 81 103
27. S.A. Lipton Neuronal injury associated with HIV-1: approaches to treatment Annu. Rev. Pharmacol. Toxicol. 38 1998 159 177
28. H. Mirchandani, and Y.W. Chien Drug delivery approaches for anti-HIV drugs Int. J. Pharm. 95 1993 1 21
29. K. Na, T. Bum Lee, K.H. Park, E.K. Shin, Y.B. Lee, and H.K. Choi Self-assembled nanoparticles of hydrophobically-modified polysaccharide bearing vitamin H as a targeted anti-cancer drug delivery system Eur. J. Pharm. Sci. 18 2003 165 173
30. D.E. Owens 3rd, and N.A. Peppas Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int. J. Pharm. 307 2006 93 102
31. G. Pantaleo, C. Graziosi, J.F. Demarest, L. Butini, M. Montroni, C.H. Fox, J.M. Orenstein, D.P. Kotler, and A.S. Fauci HIV infection is active and progressive in lymphoid tissue during the clinically latent state of disease Nat. Biotechnol. 1993 362
32. K.S. Rao, A. Ghorpade, and V. Labhasetwar Targeting anti-HIV drugs to the CNS Expert. Opin. Drug Deliv. 6 2009 771 784
33. M.J. Santander-Ortega, A.B. Jodar-Reyes, N. Csaba, D. Bastos-Gonzalez, and J.L. Ortega-Vinuesa Colloidal stability of pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms J. Colloid Interface Sci. 302 2006 522 529
34. V. Schafer, H. von Briesen, R. Andreesen, A.M. Steffan, C. Royer, S. Troster, J. Kreuter, and H. Rubsamen-Waigmann Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting Pharm. Res. 9 1992 541 546
35. L.K. Shah, and M.M. Amiji Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS Pharm. Res. 23 2006 2638 2645
36. R. Shegokar, and K.K. Singh Nevirapine nanosuspensions for HIV reservoir targeting Pharmazie 2011 10.1691/ph.2011.0317
37. R. Shegokar, M. Jansch, K.K. Singh, and R.H. Müller In-vitro protein adsorption studies on nevirapine nanosuspensions for HIV chemotherapy Nanomed. Nanotechnol. Biol. Med. 7 2011 333 340
38. E.L. Streck, G. Scaini, G.T. Rezin, J. Moreira, C.M. Fochesato, and P.R. Romão Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity Metab. Brain Dis. 23 2008 485 492
39. G. van't Klooster, E. Hoeben, H. Borghys, A. Looszova, M.P. Bouche, F. van Velsen, and L. Baert Nanosuspension of rilpivirine (TMC278) as a long-acting injectable antiretroviral formulation: pharmacokinetics and disposition Antimicrob. Agents Chemother. 54 2010 2042 2050
40. T.K. Vyas, L. Shah, and M.M. Amiji Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites Expert. Opin. Drug Deliv. 3 2006 613 628
41. U. Wattendorf, O. Kreft, M. Textor, G.B. Sukhorukov, and H.P. Merkle Stable stealth function for hollow polyelectrolyte microcapsules through a poly(ethylene glycol) grafted polyelectrolyte adlayer Biomacromolecules 9 2008 100 108
42. M. Yazdanian, and S.L. Glynn Nevirapine has excellent blood brain barrier permeability and absorption properties compared to other HIV antiretrovirals Int. Conf. AIDS 1016 1998 abstract no. 60086
43. K. Yoncheva, S. Gomez, M.A. Campanero, C. Gamazo, and J.M. Irache Bioadhesive properties of pegylated nanoparticles Expert Opin. Drug Deliv. 2 2005 205 218